FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Noseda Alessandro		 2. Issuer Name and Ticker or Trading Symbol

REGENERX BIOPHARMACEUTICALS INC [ RGRX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O REGENERX BIOPHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 470		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/17/2022
(Street)

ROCKVILLE, MD 20850
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $0.2100            (1)5/15/2029 Common Stock 200000  200000 D  
Stock Option (right to buy) $0.3000            (2)6/10/2030 Common Stock 200000  200000 D  
Stock Option (right to buy) $0.2800            (3)8/2/2031 Common Stock 240000  240000 D  
Stock Option (Right to Buy) $0.19 5/17/2022  A   240000     (4)5/17/2032 Common Stock 240000 $0 240000 D  
Explanation of Responses:
(1) 100% vested.
(2) 50,000 shares vest on each of 6/10/20, 6/10/21, 6/10/22 and 6/10/23.
(3) 60,000 shares vest on each of 8/2/21, 8/2/22, 8/2/23 and 8/2/24.
(4) 120,000 shares vest on each of 5/17/22 and 5/17/23.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Noseda Alessandro
C/O REGENERX BIOPHARMACEUTICALS, INC.
15245 SHADY GROVE ROAD, SUITE 470
ROCKVILLE, MD 20850		X
Signatures
/s/ Andrew Nick as attorney-in-fact for Alessandro Noseda pursuant to a power of attorney previously filed.5/19/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
RegeneRX Biopharmaceutic... (CE) (USOTC:RGRX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 RegeneRX Biopharmaceutic... (CE) 차트를 더 보려면 여기를 클릭.
RegeneRX Biopharmaceutic... (CE) (USOTC:RGRX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 RegeneRX Biopharmaceutic... (CE) 차트를 더 보려면 여기를 클릭.